drugset / Trial / NCT02669433

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

NCT02669433

Phase 2 Completed 484 enrolled Axovant Sciences Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.

Timeline

Start
2016-01
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject intepirdine Small molecule 35 mg Oral
Subject intepirdine Small molecule 70 mg Oral

Indications